Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT06581406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Lead sponsor
Replimune, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 17, 2024
Completion date
October 31, 2031
Enrollment
280 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma